Visual screening for malignant melanoma: A cost-effectiveness analysis

Archives of Dermatology

Volumn 143, Issue 1, 2007, Pages 21-28

  Losina, Elena ^a   Walensky, Rochelle P ^b   Geller, Alan ^c   Beddingfield III, Frederick C ^d   Wolf, Lindsey L ^b   Gilchrest, Barbara A ^c   Freedberg, Kenneth A ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; HUMAN; INCIDENCE; MELANOMA; MORTALITY; PREVALENCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; UNITED STATES;

BOSTON; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HUMANS; INCIDENCE; MARKOV CHAINS; MASS SCREENING; MELANOMA; MIDDLE AGED; PREVALENCE; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; SENSITIVITY AND SPECIFICITY; SIBLINGS; SKIN NEOPLASMS;

EID: 33846455886     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.143.1.21     Document Type: Article

References (45)

1. Ries LA, Eisner MP, Kosary CL, et al. SEER Cancer Statistics Review, 1975-2000. Bethesda, Md: National Cancer Institute; 2003.
2. Weir HK, Thun MJ, Hankey BF, et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control [published correction appears in J Natl Cancer Inst. 2003;95:1641]. J Natl Cancer Inst. 2003;95:1276-1299.
3. Tsao H, Rogers GS, Sober AJ. An estimate of the annual direct cost of treating cutaneous melanoma. J Am Acad Dermatol. 1998;38:669-680.
4. Cancer Facts and Figures. Atlanta, Ga: American Cancer Society; 2006. http://www.cancer.org/downloads/STT/CAFF2006PWSecured.pdf. Accessed March 13, 2006.
5. Ford D, Bliss JM, Swerdlow AJ, et al; The International Melanoma Analysis Group (IMAGE). Risk of cutaneous melanoma associated with a family history of the disease. Int J Cancer. 1995;62:377-381.
6. Koh HK. Cutaneous melanoma. N Engl J Med. 1991;325:171-182.
7. Geller AC, Sober AJ, Zhang Z, et al. Strategies for improving melanoma education and screening for men age ≥50 years: findings from the American Academy of Dermatological National Skin Cancer Screening Program. Cancer. 2002;95:1554-1561.
8. Geller AC. Screening for melanoma. Dermatol Clin. 2002;20:629-640.
9. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13:322-338.
10. Surveillance, Epidemiology, and End Results (SEER) Program public-use data (1973-1999). National Cancer Institute, Dept of Cancer Control and Population Science, Surveillance Research Program, Cancer Statistics Branch. Released April 2001, based on the November 2000 submission. http://seer.cancer. gov/csr/1973_1999/melanoma.pdf. Accessed October 24, 2006.
11. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635-3648.
12. Koh HK, Geller AC. Melanoma and skin cancer control: an international perspective. Cancer Control. 1995;2:385-391.
13. Freedberg KA, Geller AC, Miller DR, Lew RA, Koh HK. Screening for malignant melanoma: a cost-effectiveness analysis. J Am Acad Dermatol. 1999;41:738-745.
14. Dobson A, DaVanzo J, Kerns J. Cost Estimates for Expanded Medicare Benefits: Skin Cancer Screening, Medically Necessary Dental Benefits, and Immunosuppressive Therapy for Transplant Recipients. Washington, DC: Institute of Medicine, National Academy Press; 1999.
15. Chen SC, Bendeck SE, Hadley JC, et al. Canmelanoma patients predict the quality of life impact of an alternate melanoma stage? Presented at the 26th Annual Meeting of the Society for Medical Decision Making; October 18, 2004; Atlanta, Ga.
16. Balch CM, Houghton AN, Milton GW, Sober AJ, Soong SJ, eds. Cutaneous Melanoma. 2nd ed. Baltimore, Md: Lippincott Williams & Wilkins; 1992.
17. American Joint Committee on Cancer. Manual for Staging of Cancer. 4th ed. Philadelphia, Pa: JB Lippincott; 1992.
18. Shumate CR, Urist MM, Maddox WA. Melanoma recurrence surveillance: patient or physician based? Ann Surg. 1995;221:566-571.
19. Arias E. Life table for the total population: United States, 2000 [Table 1]. In: United States Life Tables, 2000. Vol 51. Hyattsville, Md: National Center for Health Statistics; 2002:7-8. National Vital Statistics Reports. No. 3. http://www.cdc.gov/nchs/data/nvsr/nvsr51/nvsr51_03.pdf. Accessed October 25, 2006.
20. Gold MR, Siegel JE, Russel LB, Weinstein M. Cost-effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
21. Grin CM, Kopf AW, Welkovich B, Bart RS, Levenstein MJ. Accuracy in the clinical diagnosis of malignant melanoma. Arch Dermatol. 1990;126:763-766.
22. Fryback DG, Dasbach EJ, Klein R, et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making. 1993;13:89-102.
23. Cantor SB. Cost-effectiveness analysis, extended dominance, and ethics: a quantitative assessment. Med Decis Making. 1994;14:259-265.
24. Salzmann P, Kerlikowske K, Phillips K. Cost-effectiveness of extending screening mammography guidelines to include women 40 to 49 years of age. Ann Intern Med. 1997;127:955-965.
25. Goldie SJ, Kim JJ, Wright TC. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynecol. 2004;103:619-631.
26. Frazier AL, Colditz GA, Fuchs CS, Kuntz KM. Cost-effectiveness of screening for colorectal cancer in the general population. JAMA. 2000;284:1954-1961.
27. Coley CM, Barry MJ, Fleming C, Fahs MC, Mulley AG. Early detection of prostate cancer. Part II: Estimating the risks, benefits, and costs. American College of Physicians. Ann Intern Med. 1997;126:468-479.
28. US Preventive Services Task Force. Guide to clinical preventive services. http://www.ahrq.gov/clinic/cps3dix.htm#cancer. Accessed March 14, 2006.
29. Pignone M, Saha S, Hoerger T, Mandelblatt J. Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the US Preventive Services Task Force. Ann Intern Med. 2002;137:96-104.
30. Mandelblatt J, Saha S, Teutsch S, et al. The cost-effectiveness of screening mammography beyond age 65 years: a systematic review for the US Preventive Services Task Force. Ann Intern Med. 2003;139:835-842.
31. Weinstein MC, Goldie SJ, Losina E, et al. Use of genotypic resistance testing to guide HIV therapy: clinical impact and cost-effectiveness. Ann Intern Med. 2001;134:440-450.
32. Goldman L. Cost-effectiveness in a flat world: can ICDs help the United States get rhythm? N Engl J Med. 2005;353:1513-1515.
33. Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med. 2003;163:1637-1641.
34. Beddingfield FC III. Melanoma: a decision analysis to estimate the effectiveness and cost-effectiveness of screening and an analysis of the relevant epidemiology of the disease. http://www.rand.org/publications/RGSD/ RGSD167/. Accessed March 14, 2006.
35. Girgis A, Clarke P, Burton RC, Sanson-Fisher RW. Screening for melanoma by primary health care physicians: a cost-effectiveness analysis. J Med Screen. 1996;3:47-53.
36. Cristofolini M, Bianchi R, Boi S, et al. Analysis of the cost-effectiveness ratio of the health campaign for the early diagnosis of cutaneous melanoma in Trentino, Italy. Cancer. 1993;71:370-374.
37. US Preventive Services Task Force. Screening for skin cancer: recommendations and rationale. Am J Prev Med. 2001;20:44-46.
38. Field MJ, Lawrence RL, Zwanziger L, eds; Committee on Medicare Coverage Extension, Institute of Medicine. Extending Medicare Coverage for Prevention and Other Services. Washington, DC: National Academy Press; 2000.
39. Gohagan JK, Prorok PC, Hayes RB, Kramer BS. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Control Clin Trials. 2000;21:251S-272S.
40. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg. 1970;172:902-908.
41. Ness RM, Holmes AM, Klein R, Dittus R. Cost-utility of one-time colonoscopic screening for colorectal cancer at various ages. Am J Gastroenterol. 2000;95:1800-1811.
42. Ferrone CR, Ben Porat L, Panageas KS, et al. Clinicopathological features of and risk factors for multiple primary melanomas. JAMA. 2005;294:1647-1654.
43. Slingluff CL Jr, Vollmer RT, Seigler HF. Multiple primary melanoma: incidence and risk factors in 283 patients. Surgery. 1993;113:330-339.
44. Hill L, Ferrini RL. Skin cancer prevention and screening: summary of the American College of Preventive Medicine's practice policy statements. CA Cancer J Clin. 1998;48:232-235.
45. Wright JC, Weinstein MC. Gains in life expectancy from medical interventions: standardizing data on outcomes. N Engl J Med. 1998;339:380-386.